Dutasteride in the treatment of frontal fibrosing alopecia: Systematic review and meta‐analysis

Abstract

AbstractFrontal fibrosing alopecia (FFA) is a scarring alopecia with fronto‐temporo‐parietal hairline recession. Although no proven treatment for FFA exists, dutasteride has been suggested as a potential treatment option. We aimed to evaluate the therapeutic response of oral dutasteride in FFA patients. The identification and selection of studies were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐analysis 2020 criteria. To assess the risk of bias for each study, we used the Cochrane's risk of bias in non‐randomized studies of interventions (ROBINS‐I) assessment tool. A random effects model meta‐analysis was performed. Estimated proportion of stabilization for eligible studies was calculated to evaluate the effectiveness of dutasteride for treating FFA. Among patients who achieved stabilization, subgroup analysis was conducted on those showing improvement. Seven studies including 366 patients who received oral dutasteride were identified. The estimated proportion of patients who experienced stabilization of FFA with oral dutasteride was 0.628 (95% CI: 0.398–0.859). In subgroup analyses of patients who experienced improvement, the estimated proportion of improvement was 0.356 (95% CI: 0.163–0.549). In this systematic review and meta‐analysis, oral dutasteride revealed to be a good treatment option for disease stabilization or improvement in patients with FFA.